Companies
CCIT
academic TIL programs at cancer institutes.
- Country
- Denmark
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Affiliation | Herlev Hospital, Department of Oncology, Copenhagen University Hospital | dccc.dk |
| Research focus | cancer immunology and immunotherapy, focusing on experimental and clinical research, including TIL therapy and tumor microenvironment modulation | phd-ccr.ku.dk · research.regionh.dk · dccc.dk |
| Facility | GMP certified laboratory for the preparation of therapeutic immunological cellular products | dccc.dk |
| Headcount | Approximately 56 to 70 employees | dccc.dk |
| Principal staff | Inge Marie Svane, Per Thor Straten, and Mads Hald Andersen (Directors/Professors); Özcan Met (Head, Cell Therapy Unit) | phd-ccr.ku.dk · dccc.dk |
Independent sources: dccc.dk · phd-ccr.ku.dk · research.regionh.dk
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| TIL therapy (tumor-infiltrating lymphocytes) | therapeutics-platforms | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.